Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Malignancies have been described in patients receiving anti-TNF therapy although the risk appears to be small. These agents are generally avoided in patients with a history of malignant disease because of the concern that inhibiting TNF may lead to a recurrence or progression of malignancy. To date, no study has specifically asked whether TNF blockade increases the risk of recurrent cancer in patients with previous malignancy. This chapter provides a summary of the associations between anti-TNF therapy and malignancy and offers practical advice when considering these therapies in patients with a history of malignant or premalignant disease. © 2011 Blackwell Publishing Ltd..

Original publication





Book title

Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges: Second Edition

Publication Date



136 - 139